PROGRAM MOUNTS BAY ROAD, PERTH, WESTERN AUSTRALIA 49TH ANNUAL SCIENTIFIC MEETING PERTH CONVENTION ANDEXHIBITIONCENTRE, SATURDAY 14MAY TO TUESDAY 17MAY 2016

INCLUDES: SUNDAY 15MAY TO TUESDAY 17MAY 2016 3RD ANNUAL MEETING AUSTRALASIAN SOCIETY OFCOSMETIC DERMATOLOGISTS SATURDAY 14MAY ANDSUNDAY 15 MAY15TH NATIONAL 2016 CONFERENCE AUSTRALIAN DERMATOLOGY NURSES’ ASSOCIATION

www.dermcoll.edu.au

PERTH _ AUSTRALIA’S SUNNIEST CAPITAL CITY WELCOMES YOU TO THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

WELCOME FROM THE PRESIDENT

Welcome to Perth, Western Australia for the 49th Annual Scientific Meeting of the Australasian College of Dermatologists. Enclosed in this brochure is the program and other important information for the meeting along with the programs for the meetings of the Australian Dermatology Nurses’ Association and the Australasian Society of Cosmetic Dermatologists.

The local organising committee was this year headed by Dr Daniel Hewitt, FACD, and supported by the College’s Scientific Meetings Steering Committee. The Western Australia Faculty welcomes Fellows, trainees, students and other medical practitioners to the meeting.

2 I am excited to welcome our overseas speakers: Professor John McGrath, Professor of Molecular Dermatology and Head of the Genetic Skin Disease Unit at St John’s Institute of Dermatology, King’s College London, United Kingdom. Professor Peter Mortimer, Professor of Dermatological Medicine at St George’s, University of London, United Kingdom. Professor Dirk Elston, Professor and Chairman of the Department of Dermatology and Dermatologic Surgery at the Medical University of South Carolina, Charleston, United States of America. Professor Clark Otley, Chair of the Department of Dermatology and Professor of Dermatology at Mayo Clinic in Rochester, Minnesota, United States of America.

Speakers participating in sponsored sessions: Dr Miriam Bettencourt Prof. Thomas Bieber Prof. Malcolm Hopwood Dr Brian Nickoloff Dr. Joey Kaye Dr. Lena Thin Dr. John Dixon

International speakers in the Australasian Society of Cosmetic Dermatologists Meeting: Dr Steve Eubanks Dr Klauss Hoffman Dr Gary Monheit Dr Sandeep Cliff Dr Ron Moy Dr Yohei Tanaka

Other invited speakers: Prof. Peter Leedman Prof. Steven Thng Dr Tim Inglis

The meeting has been strongly supported by the pharmaceutical and allied health industries as sponsors and trade exhibitors. I invite all delegates to visit the displays in the trade exhibition, to meet the industry representatives and to learn about new developments in products and services. It is with the very generous support of our sponsors and exhibitors that the College is able to hold a meeting of this size and quality. I hope you all find this meeting a worthwhile and enjoyable experience.

A/Prof. Christopher Baker, FACD

3 BOARD OF DIRECTORS 2015/2016

A/Prof Chris Baker President Dr Andrew Miller President-Elect Dr Andrew Satchell Honorary Secretary Dr Adrian Lim Dean of Education Dr David Cook Elected Director (NSW) Dr Alan Donnelly Elected Director (WA) Dr Robert I Kelly Elected Director (VIC) Dr Anne Lewis Elected Director (SA) Dr Michael Pitney Elected Director (QLD)

MEMBERS OF THE COLLEGE

Dr R.W. Denisenko Dr S. de Zwaan Dr E. Doherty NEW SOUTH WALES Dr S. Donoghue FACULTY Dr C.J. Drummond Dr K.J. Dunlop Dr N.S. Agar Dr P.K. Dwyer Dr P. Alexander Dr K. Engeti Prof. C. Anderson Dr H. Fallah Dr F.E. Anderson* A/Prof. P. Fernandez-Peñas Dr R.P. Armati A/Prof. G. Fischer Dr S. Arnold Dr J. Fisher Dr P. Artemi Dr B. Florance, RFD, RD* Dr N. Aspres Dr J. Foo* Dr S. Bakis-Petsoglou Dr P.C. Frederiksen Dr M. Bannister Dr P.A. Freeman Emer. Prof. R.St.C. Barnetson Dr S. Freeman Dr L.D. Bear Prof. K. Georgouras, OAM Dr G. Becker Dr D. Gillam Dr P. Brown Dr R. Gillespie Dr G.D. Cains Dr T.K. Gilmour Dr H. Chan Dr G. Gottschalk Dr J.C. Chapman Dr E. Gow Dr P.G. Chee Dr I. Grigoris Dr K. Chen Dr K. Gudmundsen Dr J.Y.J. Choi Dr P. Guitera Dr E.Y.Y. Chow Dr M. Gupta Dr E. Christou Dr R. Gupta Dr R. Cocciolone Dr I.D. Hamann Cl. A/Prof. C.A. Commens Dr R.S. Hannaford Dr D.K. Cook Dr R. Harvey Dr N. Cook Dr M.F. Healsmith Prof. A.J. Cooper, OAM Dr S. Heiman Dr G. Cottee Dr K.K-L. Ho Dr A.E. Cronin* Dr P. Hogan Dr K.A. Crotty Dr D. Holt Prof. D.L. Damian Dr E. Hong Dr D.E. Davies Dr R. Howes Dr E. Dawes-Higgs Dr M.J. Hunt Dr J.W. de Launey Dr N.T. Huynh Dr W.E. de Launey

4 Dr F. Isaacs Dr V. Paddon Dr A. Wegman Dr N, Jang Dr B.K-C. Pang Dr P.A. Weller Dr D. Jenkins A/Prof. K. Parsi Dr J. Wells Dr M. Jones-Caballero Dr A. Patel Prof. W. Weninger Dr S. Kalouche A/Prof. R.D. Paver Dr L. Wheeler Dr C.R. Kearney Dr R.D. Peek Dr H.A.D. White, AM, RFD Dr S. Khurana Dr T.A. Phan Dr M. Whitfeld Dr C. Koh Dr T.S.C. Poon Dr E. Willsteed Dr J. Konya Dr E. Pritchard Dr N. Wines A/Prof. S. Kossard Dr V. Pua Dr R. Wittal Dr J.F.C. Krivanek Dr W. Regan, AM Dr D.Y-S. Wong Dr J.M. Kuchel Dr J.P. Relic Dr D.A. Wong Dr A. Kumar Emer. Prof. S.W. Richards Dr K.C-W. Wong Dr A. Kurien Dr C.A. Riordan Dr L-C.F. Wong Dr A-M. Kurzydlo Dr J. Robinson Dr G. Wood, AM Dr E. Lamrock Dr M. Rogers Dr J. Woods Dr W.A. Land, AM, RFD, AE Dr R.H. Rosen Dr E. Yiasemides Dr M.M. Lane-Brown Dr D. Rubel Dr J. Yip Dr K.H. Le Dr W.J. Ryman Dr I.R. Younger Dr M-L. Lee Dr R.M. Salmon A/Prof. S.S. Zagarella Dr M-S. Lee Dr A.C. Satchell Dr M. Lee Dr C.A. Saywell Dr P.A. Lee Dr L. Saywell Dr S.H. Lee Dr A.C.Y. See QUEENSLAND FACULTY Cl. Prof. S. Lee, AM Dr J-A. See Dr J.L. Le Guay Dr J.F. Shannon Dr N. Abbott Dr M. Leibowitz A/Prof. S.P. Shumack, OAM Dr C.D.Y. Adib Dr L.J. Leow Dr S.E. Sinclair Dr M.L. Andrews Dr J. Lewis Dr J.R.A. Sippe Dr J.C. Auld Dr M. Li Dr G. Sivapirabu Dr H. Avery Dr A. Lim Dr A. Smth Dr S. Baghaei Dr P. Lim Dr S. Smith Dr L. Banney Dr T.K. Lipscombe Dr S.K. Sohal Prof. G.L. Beardmore (deceased 26 Dr M. Llewellyn Dr D.G. Stanford October 2015) Dr E. Lobel Dr K.M. Stapleton Dr K.E. Behne Dr M.S. Loghdey Dr E. Starritt Dr I. Browne Dr P.M. Lowe Dr A. Steele-Smith Dr D. Burdon-Jones Dr M. Lowes Dr J. Steele-Smith* Dr G.J. Butler Dr J. Mackay Dr R.B.H. Stephens Dr J.L. Byth Dr A.R. Mackenzie-Wood Dr M. Stewart Dr B. Carew Dr L. Martin Dr N. Stewart Dr T. Casey Dr J. Matulich Dr H.M. Studniberg Dr J.E.D. Chick Dr I.D. McCrossin Dr J.R. Sullivan Dr K-Y. Choong Dr R.R.A. McDonald Dr M.C. Symons Dr D. Coates Dr S. McDonald Dr M. Tam Dr J.G. Coates Dr B. McGaw* Dr F.J. Tefany Dr N.J. Collins Dr C. McKay Dr K.E. Thai Dr B-I. Cominos Dr M. McRae Dr C.H.F. Thoo Dr S. Congdon Dr A.C. Miller Dr N. Todes-Taylor Dr S.L. Conias Dr A. Ming Dr A. Tomizawa Dr C. Curchin A/Prof. F. Moloney Dr A. Varol Dr T.A. Darben Dr G. Moreno Bonilla Dr S. Venugopal Dr S. Davidson Dr C. Morrow Dr M.S. Wade Dr B.J. De’Ambrosis Dr A.St.L. Moss Dr E. Waine Dr K. DeAmbrosis Dr E. Mullan Dr B. Wallace Dr R.M. De Voss Prof. D. Murrell Dr R. Walther Dr A.J. Dore Dr S.Y. Ng A/Prof. O. Wargon, OAM Dr C.F. Faulkner Dr R.T.D. Nguyen Dr R. Watchorn Dr D.B. Francis Dr A. O’Neill Dr A.B. Watson Dr M.G. Freeman Dr C.S-C. Ong Dr G.C. Watt Dr G. Frost

5 Dr Z.S. Gaspar Dr L. Wheller Dr R. Gild Dr P.R. Wilson Dr A.M. Godbolt Dr J.K-H. Wu A/Prof. N. Haass Dr S.A. Yong-Gee VICTORIAN FACULTY Dr M.W. Harley Dr C. Yoong Dr A.N.R. Amerasinghe Dr A. Herat Dr T. Zappala Dr K. Armour Dr R.J. Hills A/Prof. C.S. Baker Dr G.J. Holmes Dr J. Banky Dr B. Jones Dr P.S. Bekhor Dr L.J. Kelly* SOUTH AUSTRALIAN Dr P.A. Berger A/Prof. K. Khostrotehrani FACULTY Dr N.R. Bleasel Dr Y.J. Kim Dr S. Anabarasu Dr T. Bohl Dr S. Kumar Dr P. Armenores Dr A. Boyapati Dr Y.N. Lau Dr S. Ball Dr A. Boyce Dr C.T. Lee Dr C. Black Dr A. Braue Dr K-C. Lee Dr M. Black Dr B. Breadon Dr Y. Lee Dr G. Casey Dr J.A. Brenan* (deceased 20 March Dr D.F. Leslie Dr E. Christou 2016) Dr D. Lim Dr R.M. Czechowicz Dr S.K. Brennand Dr K.R. Lun Dr C.M. Duguid Dr F.J. Bruce Dr S. Manoharan Dr E. Ellis Dr J.C. Burford Dr I. McColl Dr L. Gordon Dr J.M. Butler, AM Dr P.L. McLaran Dr N.L. Grieve Dr J. Cahill Dr E. McMeniman Dr M.J.A. Hanna Dr A.W. Callan Dr C.H. Mercer Dr E. Haverhoek Dr N.J. Callan Dr P.M. Millar Dr D.C. Hill Dr J. Cargnello Dr R.MacD. Miller A/Prof. S.C. Huilgol Dr T. Carner Dr A.B. Mirza Dr S. Khoury Dr A. Catona Dr J.B. Muir Dr J. Kirk (deceased 10 April 2016) Dr A.J. Chamberlain Dr A.J.D. Mulholland Dr K.J. Koh Dr S. Chandra Dr R.R. Noakes Dr Y-C. Lee Dr V. Chitreddy Dr M.A. Oziemski Dr A.E. Lewis Dr A.H.O. Chong Dr S.M. Ozluer Dr D. Long Dr A.C. Ciconte Emer. Prof. J.A. Pagliaro Dr H. Ly Dr T.J. Connors Dr C. Petherbridge* Dr R. Manifold Dr P.S.J. Cowen Dr M.J. Pitney Dr G. Marshman Dr R.B. Crouch Dr W.W. Pruim Dr J. Menz Dr P.A. Curnow Dr S. Reid Dr S.C. Murray Dr R. De Cruz Dr I.M. Robertson Dr K. Newland Dr R.L.S. Dickinson Dr K.H. Rodins Dr J. Nicolson Dr H. Dinh Dr C. Sander Dr V.F. O’Brien Dr C. Dolianitis Dr M.S. Saywell Dr C.G-G. Ooi Dr N.P. Downes A/Prof. H. Schaider Dr C.J. Parker Dr R. Dunn Dr M.P. Sharkey Dr A.L. Pearce Dr D. Dyall-Smith Dr V.L. Shepherd Dr C. Reid Dr S. Eisman A/Prof. G.M. Siller Dr E. Ryan Dr B.R. Entwisle* Dr P.R. Sinclair Dr P.A. Selva-Nayagam Dr P.E. Fergin Dr R.J. Sinclair Dr K. Shirato Dr E. Finkelstein Prof. H.P. Soyer Dr S.K. Sidhu Dr A. Fitzgibbon Dr L.J. Spelman Dr I.J. Simmons A/Prof. P.A. Foley Dr G.J. Stephenson Dr D. Tilakaratne Dr D. Gan Dr P. Teng Dr C.J. Tyson Dr D.V. Gill Dr S. Tritton Dr S. Vaidya A/Prof. S. Gilmore Dr S. Tucker Dr P.C. Walker A/Prof. D. Gin Dr F.J. van der Walt Dr L.J. Warren Dr M.S.Y. Goh Dr Y.Y. Vun Dr J.A. Wayte A/Prof. G.J. Goodman Dr G.H. Wagner Dr W. Weightman Dr J. Green Dr S.D. Waite Dr J. Wesley Dr C. Grills Dr S. Webber Dr T.P. Wiadrowski Dr S. Gunatheesan Dr J.W. Wells Dr L.M. Wilson

6 Dr S. Gupta Dr A. Rudd Dr A.M. Donnelly Dr L.R.S. Hale Dr R. Ruiz Araujo Dr T.G. Elliott A/Prof. A.P. Hall Dr T.J. Rutherford Dr R. Foster Dr S.C. Harrison Dr K. Sandhu Dr G. Foxton Dr M.I. Haskett Dr A. Saracino Dr H. Gebauer Dr E. Hiscutt Dr H.L. Saunders Cl. A/Prof. K. Gebauer Dr J. Horton Dr L.V. Scardamaglia Dr R. Granger A/Prof. Dr A. Howard Dr C.E. Scarff Dr A.R. Halbert Dr C. Jalilian Dr C. Schofield Dr W.K. Hedley Dr W.J. Jamieson* Dr A.H. Segal Dr D. Hewitt Dr A. Jevtic Dr M. Seith Dr C. Heyes Dr A. Jopp-McKay Dr N. Sharma A/Prof. P. Kumarasinghe Dr S. Joseph Dr P. Sharma Dr D. Lim Dr J.R. Kelly* Dr D.A.R. Shephard Dr G. Masel A/Prof. J.W. Kelly Dr A. Sheridan Dr G. Moloney Dr R.I. Kelly Dr N. Shim Dr W.B. Muston* Dr J. Kern Dr P.A. Sinclair Dr K.M. Opie Dr P.J. Lane Prof. R.D. Sinclair Dr L.M. Pepall A/Prof. M.J. Sladden Dr D. Lanzer Dr C.J. Quirk Dr A. Lasocki Dr A. Stavrakoglou Dr P.L. Randell Dr A.Y.L. Lee A/Prof. J.C. Su Dr B. Ricciardo Dr M.W-K. Lee Dr E.H. Taft, AM* Dr J.B. Rohr Dr S-W. Lim Dr M.M. Tam Dr G.M. Sadler Dr W. Liu Dr B.T. Tan Dr D. Singh Dr E. Ma Dr E. Tan Dr G.D. Singh Dr R. Mak Dr B.J. Tate Dr P. Singh Dr A.W-Y. Mar Dr D. Tran Dr T.M. Skender-Kalnenas Dr V. Mar Dr A. Tuxen Dr H. Smith Prof. R. Marks, AM Dr E.J.McK. Upjohn Dr P.T. Swarbrick Dr D.M. McColl Prof. G.A. Varigos Cl. A/Prof. C.J. McCormack Dr A. Verma Dr Y.J. Tai Dr C. McDonald Dr F. Y-Y. Watkins Dr C.P. Tait Dr C.J. Meehan Dr M.R. Webster Dr E.B.C. Tan Dr A.C. Michaelides Dr B.M. Welsh Dr G.A. Thom Dr O. Milne Prof. I. Winship Dr J. Tu Dr M. Mohamed Dr K. Wolfowitz Dr E. Veysey Dr V.A. Morgan Dr L-M. Yap Cl. A/Prof. C. Vinciullo Dr M.L.L. Moyle Dr A. Yazdabadi Dr J.A. von Nida Dr J. Ng Dr J.M. Yeatman Dr L.M. Wall Dr J. Nicolopoulos Dr L. Yip Dr S. Weston A/Prof. R. Nixon Dr L. Young Dr D.S. Nurse* Dr T.J. O’Brien Dr R.J. O’Keefe Dr J.M. Opie RESIDENT IN NEW WESTERN AUSTRALIAN ZEALAND Dr D.C. Orchard FACULTY Dr M. Palmer Dr J.D. Adams Dr J. Adamson Dr V. Palmer Dr L.M. Armstrong* (SA Faculty) Dr J.H. Allison* Dr Y. Pan Dr W.J. Burton (NSW Faculty) Dr K. Borchard Dr A. Perez De Velasco Dr T. Gunson (WA Faculty) Dr R. Brand Dr E.C-H. Poon Dr M. Heng Dr T. Caccetta Dr B. Rajagopalan Dr M.W. Hursthouse (SA Faculty) Dr D. Rathnayake Dr J.J.S-M. Chan Dr D. Rowan (SA Faculty) Dr G.J. Rennick Dr P. Cherian Dr P.J. Sears Dr J. Rhodes Dr H.C. Chua Dr B.C. Turnbull* (SA Faculty) Dr M.V. Rich Dr C. Clay Dr D.W. Young (VIC Faculty) Dr H. Roberts Dr J. Cole * Foundation Members Dr S. Robertson Dr B.L. Connor Dr M.A. Rodrigues Dr K.J. Dallimore Dr G.L. Ross Dr T.A. Delaney

7 HONORARY MEMBERS

Prof. E. Tschachler – Austria Cl. Prof. C.L. Goh - Singapore Prof. P. Mortimer - United Kingdom

ASSOCIATE MEMBERS

Prof. C.R. Blackburn, AC – New Dr A. Fischer – New South Wales Dr D. Muir - New South Wales South Wales (deceased 12 April Dr D.S. Forbes - New South Wales Prof. H.K. Muller - Tasmania 2016) Dr J. Fryer - New South Wales Prof. R. Penny, AO - New South Dr T.W. Beer – Western Australia Dr A. Gramp - South Australia Wales Dr P. Bullpitt – New South Wales Dr W.A.D. Griffiths - United Prof. H.M. Prince - Victoria Dr K.C. Chong – Queensland Kingdom Dr A. Ryan - Victoria Dr E.C. Cleary – South Australia Prof. G. Halliday - New South Wales Dr G. Strutton - Queensland Dr R. Crouch – New South Wales Dr P.J. Heenan - Western Australia Dr J. Sullivan – Queensland Dr A. Darling - Victoria Dr V.C. Howard – New South Wales Dr S. Swain - Victoria Dr A.P. Dorevitch - Victoria Dr C. James – South Australia Dr J. Tversky - Victoria Dr J.P. Dowling - Victoria Dr B. Kynaston – Queensland Prof. D. Weedon, AO - Queensland Dr R.E.T. Duhig – Queensland Dr J. Magee – Victoria Dr R.A. Williams - Victoria Dr B. Dutta – New South Wales Dr S. Mann – New South Wales Prof. K. Wolff – Austria Dr R.B. Dymock - South Australia Dr G. Mason - Victoria Cl. A/Prof. L. Yu – Western Australia A/Prof. D. Ellis - South Australia Miss R. McAleer, AM - Western Australia Dr J. Farnsworth - Queensland Prof. S. Menzies – New South Wales

Hands up if you’d like additional psoriasis treatments PBS listed

Visit the Celgene trade display to see how you can help

Celgene Pty Ltd ABN 42 118 998 771. Level 7, 607 St Kilda Rd, Melbourne VIC 3004, Australia. Tel 1800 CELGENE (1800 235 4363) www.celgene.com.au ®Registered Trademark. EMVOTZ0110 AU-APR0140 Date Prepared: March 2016.

8 PROGRAM

The scientific sessions of the meeting will be held in the Riverside Theatre of the Perth Convention and Exhibition Centre. Concurrent sessions will be held in Meeting Rooms 1-3.

SPECIAL EVENTS

The following satellite meetings are being held in associate with the College conference: AUSTRALIAN DERMATOLOGY NURSES’ ASSOCIATION 15TH ANNUAL NATIONAL CONFERENCE Perth Convention and Exhibition Centre Saturday 14 May and Sunday 15 May 2016 AUSTRALASIAN SOCIETY OF COSMETIC DERMATOLOGISTS 3RD ANNUAL MEETING Perth Convention and Exhibition Centre Sunday 15 May to Tuesday 17 May 2016

REGISTRATION

The Registration Desk will be located in the Level 2 Foyer. The registration desk will open on Saturday 14 May from 0700 and throughout the meeting. The College secretariat office located in Meeting Room 12 will be open from 1000 to 1600 daily.

MEET THE ACD STAFF!

The College will have its own stand located at booth 1 in the trade exhibition, manned by members of the College staff. Please meet us and learn about your College. Explore the new website, check your CPD, and discover the new initiatives and work that is ongoing within the College.

NAME BADGES

Name tags must be worn at all times. Delegates without a name badge may be refused entry to sessions and to the trade exhibition.

9 CONFERENCE APP

The College is offering a free downloadable app for the Annual Scientific Meeting. To download the app please search for ACD2016ASM in your app store.

Features of the app include: Building your own personal program of sessions Participating in the exhibition passport competition View all trade details and easily be able to contact them after the ASM

All delegates will have a QR code on their name badge which can then be used by trade to collect your details to be able to send you further information. Please see the staff at the registration desk if you are having any issues with using the app.

EXHIBITOR PASSPORT EXPLORE PERTH

This year the exhibitor passport will be During your time in Perth we hope that you will find some time to run through the conference app. Each explore! The City of Perth website has a lot of great information that trade exhibitor will have a sign at their can be found at www.visitperthcity.com. A walking tour has also been booth with a QR code. To enter the organised on Monday 16 May, details are below: competition for each booth: 1000-1230 PRIVATE ART & HISTORY WALKING TOUR OF PERTH 1. Scan the barcode at the exhibition Meeting Point: Level 1 Entrance, Perth Convention and booth using the “Scan” function in Exhibition Centre the menu of the app. Note that you A combination of Oh Hey WA’s art and history tours. Your fun loving must allow the app to access your guide Adie is a Perth enthusiast who loves sharing stories of her home phone’s camera. town. This tour will be a complete overview of the city including history, 2. A question about the exhibitor will art, bars, developments and general awesomeness of Perth. The tour pop up, please answer this question will conclude at the Perth Cultural Centre located 1km from the Perth to submit for entry for this booth. Convention & Exhibition Centre. 3. You can view all of the exhibitors Cost: $37 per person + 4% Booking Fee you have answered questions for Booking Instructions: in the “Exhibitor Passport Entries”. Note that once an answer is 1. Follow the link: submitted you cannot go back to http://www.ohheywa.com.au/booking-walking-tours-perth view or change this. 2. Select May 16 on the calendar Delegates are required to answer 20 3. Click book now on PRIVATE TOUR: exhibitor questions to qualify for a Australasian College of Dermatologists Annual Scientific Meeting complete entry. Prizes will be awarded during the lunch break on Tuesday 17 4. Continue to fill out booking details May in the Exhibition Hall.

10 TRADE EXHIBITION

The trade exhibition will be in Pavilion 1 and Pavilion 2. It will be open on the following days: Saturday 14 May from 1000 to 1600 (1245 official opening) Sunday 15 May from 1000 to 1600 Monday 16 May from 1000 to 1600 Tuesday 17 May from 1000 to 1330 The morning tea, lunch and afternoon tea breaks will be held in the trade exhibition. AWARDS FOR OUTSTANDING EXHIBITORS

Awards for the outstanding exhibits will be announced on Tuesday 17 May 2016. The categories of award are:

Most outstanding display of 9 sqm or less in size Most outstanding display of 18 sqm to 27 sqm in size Most outstanding display of 36 sqm in size, or larger The award will be decided by a panel of three judges.

SPEAKERS’ PREPARATION ROOM

The speakers’ preparation room is located in Meeting Room 11 of the Perth Convention and Exhibition Centre (opposite the Level 2 entrance to the Riverside Theatre). The room is staffed daily. The technician will be on hand one hour before the start of each session, then 30 minutes after the close of the final session. Presenters are encouraged to hand their presentations in at least two hours before required onstage, or the day before if presenting in the morning.

AWARDS

If there are papers of sufficient merit, the following prizes will be awarded:

Best research paper read at the Annual Scientific Meeting – F. & E. Bauer Foundation Prize Best paper in the Registrars’ Forum - Sponsored by Best poster presentations (two prizes) Best paper or poster presentation by a New South Wales Registrar, the Eileen Collins Memorial Prize – funded by the New South Wales Faculty Best paper in Contact Dermatitis, the John Fewings Memorial Prize – funded by the Skin and Cancer Foundation Victoria

11 PCEC - Level 1 PERTH CONVENTION AND EXHIBITION CENTRE

LEVEL 1

PCEC - Level 2

LEVEL 2

PCEC - Level 3

LEVEL 3

12 PROGRAM AT A GLANCE SATURDAY 14 MAY 2016

0700-1700 Registration of delegates and Associates, Level 2 Foyer Riverside Meeting Rooms River View River View BelleVue BelleVue Meeting Room 6 Meeting Room 7 Meeting Room 8 Theatre 1-3 Room 4 Room 5 Ballroom 1 Ballroom 2 0730-0845 ACD ASM: Janssen-Cilag Sponsored Breakfast: Past, Present and Future: The Evolving Dermatology Treatment Landscape 0845-1030 ADNA Meeting: Session One 0855-1030 ACD ASM: Mohs Educational Meeting 0900-1030 ACD ASM: Registrars' Forum – Sponsored by

0930-1030 ACD ASM: Curriculum Review 1030-1100 Morning tea in Trade Exhibition, Pavilion 1 & 2 1100-1230 ACD ASM: ADNA Meeting: ACD ASM: Mohs Multidisciplinary Session Two Educational Dermatology Meeting 1230-1330 Lunch in Trade Exhibition, Pavilion 1 & 2 1330-1430 ADNA Meeting: Session Three 1330-1500 ACD ASM: ACD ASM: Mohs Evidence Based Educational Dermatology Meeting 1430-1500 ADNA Meeting: Afternoon tea in Trade Exhibition, Pavilion 1 & 2 1500-1530 Afternoon tea in Trade Exhibition, Pavilion 1 & 2 1500-1630 ADNA Meeting: Session Four 1530-1700 ACD ASM: ACD ASM: Mohs Professionalism Educational Symposium Meeting 1715-1830 ACD ASM: Celgene Sponsored Symposium: Why Management of Psoriasis Must Extend Beyond PASI Scores 1930-2400 ACD ASM: Conference Dinner

13 PROGRAM AT A GLANCE SUNDAY 15 MAY 2016

0700-1700 Registration of delegates and Associates, Level 2 Foyer Riverside Meeting Rooms River View River View BelleVue BelleVue Meeting Room 6 Meeting Room 7 Meeting Room 8 Theatre 1-3 Room 4 Room 5 Ballroom 1 Ballroom 2 0730-0845 ACD ASM: ACD ASM: Novartis LEO Pharma Sponsored Sponsored Breakfast: Breakfast: Managing Progressing Psoriasis Evidence Patients with IL- in Actinic 17 Inhibition Keratoses to Optimise Patient Care 0900-1030 ACD ASM: ACD ASM: ADNA Meeting: Concurrent Concurrent Session Five Session 1A: Session 1B: Melanoma Symposium: Ask Symposium the Expert 1030-1100 Morning tea in Trade Exhibition, Pavilion 1 & 2 1100-1200 ADNA Meeting: Session Six 1100-1230 ACD ASM: Opening Plenary Session 1200-1300 ADNA Meeting: Lunch in Trade Exhibition, Pavilion 1 & 2 1230-1330 Lunch in Trade Exhibition, Pavilion 1 & 2 1300-1515 ADNA Meeting: Session Seven 1330-1500 ACD ASM: ACD ASM: ASCD Meeting: Concurrent Concurrent Physical Session 2A: Session 2B: Treatment of Pigmentary Paediatric Sun Damage Disorders Symposium symposium 1500-1530 Afternoon tea in Trade Exhibition, Pavilion 1 & 2 1530-1700 ACD ASM: ACD ASM: ASCD Meeting: ASCD Meeting: ASCD Meeting: Concurrent Concurrent Lasers and Lasers and Lasers and Session session 3B: Energy Based Energy Based Energy Based 3A: Contact Updates on Devices – Best Devices – Best Devices – Best Dermatitis Skin Cancer Practice Practice Practice Symposium Research, Australasian Society for Dermatology Research (ASDR) 1800-1900 Graduation Oration and Conferring of Diplomas and Awards 1900-1930 Foyer - Founders' Cocktail Party

14 PROGRAM AT A GLANCE MONDAY 16 MAY 2016

0700-1700 Registration of delegates and Associates, Level 2 Foyer Riverside Meeting Rooms River View River View BelleVue BelleVue Meeting Room 6 Meeting Room 7 Meeting Room 8 Theatre 1-3 Room 4 Room 5 Ballroom 1 Ballroom 2 0730-0845 ASCD Meeting: ACD ASM: La Syneron Candela Roche Posay Sponsored Sponsored Breakfast: Breakfast: A Overcoming Further Look the Challenge into the Skin of Unwanted Microbiome Pigmentation: and its Role Using the in Cutaneous Candela Disease PicoWay and GentleMAX Pro 0900-1030 ACD ASM: ACD ASM: ASCD Meeting: Concurrent Concurrent Skin Tightening Session 4B: Session 4A: (0850-0920) Nonmelanoma Infectious Speed Dating Skin Cancer Disease with the Trade Symposium Symposium (0920-1030) 1030-1100 Morning tea in Trade Exhibition, Pavilion 1 & 2 1100-1230 ACD ASM: Plenary 2 1230-1345 Lunch in Trade Exhibition, Pavilion 1 & 2 1345-1500 ACD ASM: ASCD Meeting: Clinical Meeting Mini plenary and Physical Treatments of Acne 1500-1530 Afternoon tea in Trade Exhibition, Pavilion 1 & 2 1530-1700 ACD Annual ACD ASM: General Meeting Registrars’ Teaching Session 1530-1645 ASCD Meeting for Non Dermatologists 1700-1830 ASCD ASM: Galderma Dummy Injecting Session

15 PROGRAM AT A GLANCE TUESDAY 17 MAY 2015

0700-1700 Registration of delegates and Associates, Level 2 Foyer Riverside Meeting Rooms River View River View BelleVue BelleVue Meeting Room 6 Meeting Room 7 Meeting Room 8 Theatre 1-3 Room 4 Room 5 Ballroom 1 Ballroom 2 0730-0845 ACD ASM: Eli Lilly Sponsored Breakfast: Patient Care in Psoriasis: Is it Time to Raise the Therapeutic Bar? 0900-1030 ACD ASM: ACD ASM: ASCD Meeting: Concurrent Concurrent The Issue of Session 5A: Session 5B: Volume Alopecia Research Symposium Symposium 1 1030-1100 Morning tea in Trade Exhibition, Pavilion 1 & 2 1100-1230 ASCD Meeting: Plenary 3: The Problem of Colour 1230-1330 Lunch in Trade Exhibition, Pavilion 1 & 2 1300-1500 ACD ASM: ACD ASM: ASCD Meeting: Concurrent Concurrent Texture Session 6A: Session 6B: Clinical Updates Research Symposium 2 1500-1515 ACD ASM: Presentation of Awards and Closing Remarks

*

That’s days to focus on life... not psoriasis * 4 = maintenance therapy after 2 induction doses For the treatment of moderate-to-severe plaque psoriasis1

PBS Information: Authority Required. Refer to the PBS Schedule for full details. Please refer to the Product Information before prescribing (available from http://www.janssen.com.au/Stelara_PI) STELARA® ustekinumab (rmc) vials MINIMUM PRODUCT INFORMATION (Plaque psoriasis, psoriatic arthritis) INDICATIONS: Moderate to severe plaque psoriasis in adults who are candidates for photo- or systemic therapy; *signs and symptoms of active psoriatic arthritis in adults where response to previous non-biological DMARD therapy has been inadequate. DOSE: Psoriasis: Subcutaneous injection. 45 mg at Weeks 0 and 4, then every 12 weeks. Alternatively, in patients weighing >100 kg, 90 mg at Weeks 0 and 4, then every 12 weeks. If inadequate response, consider treatment every 8 weeks. Discontinue if no response after 28 weeks. *Psoriatic Arthritis: 45mg at Weeks 0 and 4, then every 12 weeks. Some patients weighing >100kg received a 90mg dose in clinical trials and observed a clinical benefit.CONTRAINDICATIONS: Severe hypersensitivity to ustekinumab or to any of the excipients. Do not administer to patients with a clinically important active infection. PRECAUTIONS: Serious infections: STELARA may increase risk of infections and reactivate latent infections. Serious bacterial, fungal and viral infections have been observed. Use with caution in patients with chronic or recurrent infections. Tuberculosis (TB): Evaluate for TB prior to initiating treatment. Do not administer to patients with active TB. Treat latent TB before administration. Consider anti-TB therapy in patients with suspected TB. Monitor patients for TB. Malignancies: STELARA may increase risk of malignancies. Malignancies have been observed. Use with caution in patients with known malignancy or history of malignancies. *Patients should be monitored for the appearance of non-melanoma skin cancer. Hypersensitivity reactions: Discontinue immediately if serious hypersensitivity reactions including anaphylaxis and angioedema occurs. Immunisations: Do not give live bacterial or viral vaccines. Consider secondary transmission of live vaccines from contacts. Immunosuppression: STELARA should not be used in combination with photo- or systemic therapy. Immunotherapy: Use with caution in patients receiving allergy immunotherapy. Reversible Posterior Leukoencephalopathy Syndrome (RPLS): If RPLS is suspected, STELARA should be discontinued and appropriate therapy instituted. *Serious Skin Conditions: Physicians should be alert for symptoms of erythrodermic psoriasis or exfoliative dermatitis. STELARA should be discontinued if a drug reaction is suspected. General: Pre-filled syringe needle cover contains dry natural rubber which may cause allergic reactions. Use in Pregnancy: Category B1. ADVERSE EFFECTS: Serious: serious infections and malignancies. Very Common: nasopharyngitis and URTIs. Common: dental infections, cellulitis, viral upper respiratory tract infection, herpes zoster, depression, dizziness, headache, diarrhoea, nausea, pruritis, back pain, myalgia, arthralgia, fatigue, injection site reactions, injection site pain. Adverse events: serious cardiovascular events, suicidality, hypersensitivity (including rash, urticaria), serious hypersensitivity reactions including anaphylaxis and angioedema. PRESENTATION: Pack of 1 single use 45 mg vial. Store at 2°C – 8°C. Refrigerate. Do not freeze or shake. Protect from light by storing in original carton. Date of preparation: 27 July 2015. *Please note changes to Product Information as *italicised text REFERENCES: 1. Stelara Approved Product Information. Janssen Cilag Pty Ltd, ABN 47 000 129 975, 1-5 Khartoum Road, Macquarie Park NSW 2113 Australia. Phone: 1800 226 334 JANS1571/EMBC STE-AU-0006 Date of revision: April 2016

16 SCIENTIFIC PROGRAM SATURDAY 14 MAY 2016

THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

0700-1700 REGISTRATION of delegates and associates, Level 2 Foyer 0730-0845 JANSSEN-CILAG SPONSORED BREAKFAST: PAST, PRESENT AND FUTURE: THE EVOLVING DERMATOLOGY TREATMENT LANDSCAPE Room: BelleVue Ballroom 2 Speakers: Dr J. Kaye and Dr L. Thin Chair: Dr J. Chan A review of all biologic classes from current treatments to what you can expect to see in the future and how this may influence your treatment approach today. 0845 END OF SESSION

0900-1030 REGISTRARS’ FORUM 0855-1030 MOHS EDUCATIONAL Room: Riverside Theatre MEETING Chairs: Dr D. Hewitt and Dr R. Foster Room: Meeting Room 8 0900 Dr A. Robinson Chair: Dr P. Cherian Low-dose Rituximab and concurrent adjuvant therapy for 0855 Dr P. Cherian pemphigus: Protocol and single-centre long-term review of Welcome / twelve patients Housekeeping 0906 Dr C. Rowe 0900 A/Prof. C. Vinciullo Prognostic value of nomograms incorporating biomarkers versus Introductory speech sentinel node status in patients with stage IB and II melanoma 0910 Dr C. Otley 0912 Dr C. Rowe Survival in patients with multiple primary melanomas versus Transplant single primary melanoma dermatology: Lessons I have learned 0918 Dr L. Kunde Giant cutaneous horns: A case study and a review of the literature 0940 Dr P. Salmon 0924 Dr N. Ong Bridge flaps Outcomes of surgical management for 1010 A/Prof. C. Vinciullo suppurativa 30 years experience in 0930 Dr S. Tiwari Mohs Vismodegib in the treatment of basal cell carcinoma - Cases 1030 END OF SESSION and a review of the literature 0936 Dr A. Lee Pediatric psoriasis is associated with increased waist to height 0930-1030 CURRICULUM REVIEW ratio in the absence of obesity: A multi-centre Australian study Room: Meeting Rooms 0942 Dr A. Freeman 1-3 Modified 5-flurouracil (5-FU) chemo-wraps for the home Chair: A/Prof. S. management of intraepidermal carcinoma (IEC) and Zagarella disseminated superficial actinic porokeratoses (DSAP) 1030 END OF SESSION 0948 Dr S. Sinnya A snapshot of skin cancer prevalence in the liver transplant 1030-1100 MORNING TEA IN recipients in Queensland – Is there a role for dedicated TRADE EXHIBITION, dermatology clinics? PAVILION 1 & 2 1000 Dr A. Harris Multiple pyogenic granulomas arising spontaneously within large capillary vascular malformations during pregnancy 1006 Dr S-L. Chan Pseudo-mycosis fungoides induced by anti-tumour necrosis factor therapy 1012 Dr J. Li Mucosal-associated invariant T (MAIT) cells: What are they and what are they doing in skin? 1018 Dr T. Sivagnanam A case of juvenile temporal arteritis associated with angiolymphoid hyperplasia and eosinophilia 1024 Discussion 1030 END OF SESSION 17 SCIENTIFIC PROGRAM SATURDAY 14 MAY 2016

THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

1100-1230 MULTIDISCIPLINARY DERMATOLOGY 1100-1230 MOHS EDUCATIONAL MEETING Room: Riverside Theatre Room: Meeting Room 8 Chairs: Dr R. Foster and Dr D. Hewitt Chair: Dr P. Cherian 1100 Dr S. Townshend 1100 Masters reconstruction panel Genetic testing in melanoma Dr C. Otley 1120 Dr S. Bowyer Dr P. Salmon Update on management of metastatic Dr Y J. Tai melanoma 1200 Dr E. Tan 1140 Dr P. Boan The use of tissue glue for grafts ID – The revolution in speciation and microbiome 1210 Dr T. Gunson 1200 Dr M. Bettencourt Lessons learned Professional and ethical aspects of 1230 END OF SESSION psoriasis management 1230 END OF SESSION

1230-1330 LUNCH IN TRADE EXHIBITION, PAVILION 1 & 2

1330-1500 EVIDENCE BASED DERMATOLOGY 1330-1500 MOHS EDUCATIONAL MEETING Room: Riverside Theatre Room: Meeting Room 8 Chair: Dr R. Foster Chair: Dr P. Cherian 1330 A/Prof. S. Zagarella 1330 Dr T. Elliottt Evidenced based medicine series (bias) How I do things differently in 2016 1400 Dr G. Thom 1400 Dr R. Baker Best medical papers New anticoagulants 1430 Dr Y J. Tai 1415 Dr T. Beer Best surgical papers Pitfalls in pathology/CPC 1500 END OF SESSION 1500 END OF SESSION

1500-1530 AFTERNOON TEA IN TRADE EXHIBITION, PAVILION 1 & 2

1530-1700 PROFESSIONALISM SYMPOSIUM 1530-1700 MOHS EDUCATIONAL MEETING Room: Riverside Theatre Room: Meeting Room 8 Chairs: Dr R. Foster and Dr D. Hewitt Chair: Dr P. Cherian 1530 Dr J. Shannon 1530 Dr T. Beer Medicare and you. Audits, the commonest Pathology QAP problems/mistakes and how to avoid them 1610 Dr V. Harris 1545 Dr P. Brown An audit and review of the operation of Talking to patients is as important as Australia’s first and only public Moh’s ordering investigations surgery clinic within a tertiary referral center 1600 Dr J. Shannon 1620 Dr E. Wee Medicolegal hypothetical Retrospective audit of management and 1620 Dr A. Gupta outcomes for patients referred to The Peter Dermatology teaching in Australian MacCallum Cancer Centre following Moh’s medical schools Surgery 1630 Dr L. Abbott 1630 Dr D. Coates The smartphone consult - Evolving legal Foley catheter intraoperative tissue expansion responsibilities and vulnerabilities for following Mohs surgery dermatologists in the digital age 1640 Dr P Chen 1640 Dr W. Hunt Upper lip reconstructive conundrum Survey of Australian dermatological 1650 Dr H. Smith postoperative patient information leaflets: Are Mohs Committee Report we consistent in the guidance we provide? 1700 END OF SESSION 1650 Questions 1700 END OF SESSION

18 SCIENTIFIC PROGRAM SATURDAY 14 MAY 2016

THE AUSTRALASIAN COLLEGE AUSTRALIAN DERMATOLOGY NURSES’ ASSOCIATION 15TH OF DERMATOLOGISTS 49TH ANNUAL NATIONAL CONFERENCE ANNUAL SCIENTIFIC MEETING

1715-1830 CELGENE SPONSORED 0845-1030 SESSION ONE SYMPOSIUM: WHY Room: River View Room 5 MANAGEMENT OF PSORIASIS MUST 0845 S. Temby and A/ Prof. C. Baker EXTEND BEYOND PASI Welcome and housekeeping SCORES 0900 Dr K. Grieve Room: Riverside Theatre Moisturisers and cleansers Speakers: Cl. A/Prof. K. 1000 Prof. D. Damien Gebauer and Reduction of skin cancers with the use of nicotinamide Dr J. Wu 1030 END OF SESSION Chair: Cl. A/Prof. K. Gebauer An interactive forum 1030-1100 MORNING TEA IN TRADE EXHIBITION, PAVILION 1 & 2 led by top Australian dermatologists that will 1100-1230 SESSION TWO discuss complex cases in Room: River View Room 5 psoriasis and will cover 1100 Prof M. Schifter the following topics: Oral dermatology - Heterogeneity of 1200 State education day brainstorming psoriasis 1230 END OF SESSION - Role of inflammatory phenotypes in driving different manifestations 1230-1330 LUNCH IN PAVILION 1 & 2 of psoriasis - Difficult-to-treat areas 1330-1430 SESSION THREE - Differences between Room: River View Room 5 the perspectives of 1330 H. Rothenbuhler, RN and J. Riley, RN doctors and patients on Minor surgery symptoms, therapeutic 1400 Annual General Meeting goals and treatment options 1430 END OF SESSION 1830 END OF SESSION 1430-1500 AFTERNOON TEA IN TRADE EXHIBITION, PAVILION 1 & 2 SOCIAL PROGRAM 1500-1630 SESSION FOUR 1930-2400 CONFERENCE Room: River View Room 5 DINNER 1500 Dr T. Hughes BelleVue Ballroom Immunology 101 1530 S. Bradley, RN BDNG representative 1600 Dr C. Thomas Face to face versus tablet for patient phototherapy training 1630 END OF SESSION

19 SCIENTIFIC PROGRAM SUNDAY 15 MAY 2016

THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

0730-0845 NOVARTIS SPONSORED BREAKFAST: 0730-0845 LEO PHARMA SPONSORED BREAKFAST: MANAGING PSORIASIS PATIENTS WITH PROGRESSING EVIDENCE IN ACTINIC IL-17 INHIBITION KERATOSES TO OPTIMISE PATIENT CARE Room: BelleVue Ballroom 1 Room: BelleVue Ballroom 2 Speakers: Dr D. Rubel and Dr J. Dixon Speaker: Dr M. Bettencourt Chair: A/Prof Stephen Shumack A practical approach to integrating Picato® To explain the role of IL-17 in the gel (ingenol mebutate) into the treatment pathogenesis of plaque psoriasis and the pathway for patients with Actinic Keratoses, potential implications of its inhibition, and to presenting the use of Picato® gel for patients assess the real world evidence of psoriasis in a community dermatology practice. patients on IL-17 therapy. 0845 END OF SESSION 0845 END OF SESSION

0900-1030 MELANOMA SYMPOSIUM 0900-1030 ACNE SYMPOSIUM: ASK THE EXPERT Room: Riverside Theatre Room: Meeting Rooms 1-3 Chair: Dr E. Tan Chairs: Dr J-A. See 0900 A/Prof. N. Haass and Cl. A/Prof. K. Gebauer Developing a new melanoma drug 0900 Welcome by chairpersons 0915 A/Prof. S. Gilmore 0905 Dr M. van Steensel Increasing melanoma incidence in What really causes acne - Up to date Australia: Climate change, ozone pathogenesis depletion and overdiagnosis 0925-0945 Research papers

A 0930 A/Prof. S. Gilmore 1B 0925 Dr S. Rea Machine intelligence and decision Does isotretinoin cause depresssion? support in melanoma recognition A dermatologists’ perception and 0945 A/Prof. H. Schaider feasibility study Stress induced multi drug tolerance 0931 Dr L. Pitney precedes acquired drug resistance in Acne necrotica (necrotising lymphocytic melanoma ): An enigmatic and under 1000 Dr Y. Pan recognised dermatosis Aggressive melanoma is less likely to 0937 Dr M. Zureigat and Dr J. Rayner have histologically associated naevus Investigating GP experience - Barriers 1010 Dr S J E. Hwang and facilitators to the management Clinical and histologic assessment of and referral of acne patients and the CONCURRENT SESSION 1 SESSION CONCURRENT lichenoid/interface dermatitis observed SESSION CONCURRENT prescription of Isotretinoin in patients with advanced malignancies 0945 Dr S. Cliff on anti-Programmed cell Death-1 Skin care or what’s the best (anti-PD-1) therapy with or without moisturizer, doctor? ipilimumab 1005 Q & A with visiting speakers and local 1020 Dr C. Xie experts Does scalp location predict survival of 1025 Dr J-A. See and Cl. A/Prof. K. Gebauer head and neck melanoma? Closing remarks by chairpersons 1030 END OF SESSION 1030 END OF SESSION

1030-1100 MORNING TEA IN TRADE EXHIBITION, PAVILION 1 & 2

1100-1230 OPENING PLENARY SESSION 1 1140 Prof. J. McGrath Room: Riverside Theatre The clinical impact of molecular genetics in Chair: A/Prof. C. Baker dermatology 1100 A/Prof. C. Baker 1210 Dr S. Cliff Welcome New advances in 1110 Prof. D. Elston 1230 END OF SESSION The skin in systemic disease

1230-1330 LUNCH IN TRADE EXHIBITION, PAVILION 1 & 2

20 SCIENTIFIC PROGRAM SUNDAY 15 MAY 2016

THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

1330-1500 PIGMENTARY 1330-1500 PAEDIATRIC SYMPOSIUM DISORDERS Room: Meeting Rooms 1-3 SYMPOSIUM Chair: Dr A. Halbert Room: Riverside 1330 Prof. J. McGrath Theatre Clinical trials for inherited skin diseases: Making Chair: A/Prof. P. therapeutic progress Kumarasinghe and Dr M. 1350 Questions Rodrigues 1355 Dr V. Tng 1330 Dr M. Rodrigues cubiti: A case report and literature review What’s new in vitiligo 1400 Dr A. Robinson 1345 Dr M. Gupta Granular parakeratosis induced by benzalkonium chloride Progressive macular exposure from bath oils and laundry rinse aids 2B 2A hypomelanosis 1405 Dr S. Hill 1400 Dr N. Nagodavithana Phenotypic heterogeneity in a family with dystrophic Epidermal barrier epidermolysis bullosa: A genotypic variation? functions in 1410 Dr S. Smith progressive macular An assessment of Australian general practitioners’ knowledge hypomelanosis in about use of topical in paediatric atopic dermatitis fitzpatrick type IV/V 1415 Dr C. Zhao skin - A preliminary Fear of topical corticosteroids within Australian atopic study dermatitis patients 1410 A/Prof. S. Thng 1420 Dr G. Parham Update on melasma Carney complex and similar genetic syndromes associated 1430 A/Prof. P. with lentiginosis Kumarasinghe 1425 Dr M. Zallmann CONCURRENT SESSION SESSION CONCURRENT CONCURRENT SESSION SESSION CONCURRENT Making sense of Progressive cerebral vasculopathy in PHACE syndrome: acquired macular Detection and management in the age of propranolol hyperpigmentation of 1430 Dr M. Zallmann uncertain aetiology Magnetic resonance imaging and electroencephalography 1445 Dr H. Bhullar in asymptomatic infants with high risk-distribution port-wine Mastocytosis: A case stain: Review of the role of screening investigations series of 107 patients 1435 A/Prof. J. Su and their treatment Superfine merino wool in the management of childhood responses atopic dermatitis 1455 Discussion 1440 Dr R. Foster 1500 END OF SESSION Update on paediatric dermatology 1500 END OF SESSION

1500-1530 AFTERNOON TEA IN TRADE EXHIBITION, PAVILION 1 & 2

1530-1700 CONTACT DERMATITIS SYMPOSIUM 1530-1700 UPDATES ON SKIN Room: Riverside Theatre CANCER RESEARCH, Chair: A/Prof. R. Nixon and Dr R. Foster AUSTRALASIAN 1530 Dr J. Cahill SOCIETY FOR Interesting cases from the occupational dermatology DERMATOLOGY 3B 3A clinic RESEARCH (ASDR) Room: Meeting Rooms 1550 Dr H. Rajgopal Bala 1-3 Evaluating the Australian baseline series Chair: A/Prof. H. 1600 Dr H. Rajgopal Bala Schaider Contact dermatitis in children 1530 Prof. D. Damian 1610 Dr C. Higgins 1541 A/Prof. P. Fernandez-Penas Skin reactions to sunscreens in a Victorian patch-test population: A cross-sectional study 1552 A/Prof. N. Haass 1620 Dr D. Maor 1603 Dr V. Mar Skin contact with a stinging tree needing ICU admission 1614 A/Prof. K. Khosrotehrani 1630 Dr J. Johnston 1625 A/Prof. H. Schaider An open label study assessing the tolerability and 1636 Prof. R. Sinclair CONCURRENT SESSION SESSION CONCURRENT CONCURRENT SESSION SESSION CONCURRENT efficacy of superfine merino wool fabric in the 1647 Prof. P. Soyer treatment of atopic dermatitis 1658 Dr J. Kern 1640 Discussion 1710 END OF SESSION 1700 END OF SESSION

21 SCIENTIFIC PROGRAM SUNDAY 15 MAY 2016

AUSTRALASIAN SOCIETY OF COSMETIC AUSTRALIAN DERMATOLOGY NURSES’ DERMATOLOGISTS 3RD ANNUAL MEETING ASSOCIATION 15TH ANNUAL NATIONAL CONFERENCE

1330-1500 PHYSICAL TREATMENT OF SUN DAMAGE 0900-1030 SESSION FIVE Room: River View Room 4 Room: River View Room 5 Chair: Dr S Manoharan 0900 C. Heal 1330 Dr R. Moy Surviving melanoma Treatment of sun damage with 0930 D. Thompson, RN radiofrequency, laser and PDT Patient education framework 1350 Dr G. Monheit 1000 D-A. Cullen, RN Peels in the treatment of sun damage The nurses role in MOHS surgery in a 1410 Dr R. Moy regional setting Skin care for the prevention and treatment 1030 END OF SESSION of sun damage 1430 Case studies for discussion with Drs Moy and Monheit 1030-1100 MORNING TEA IN TRADE EXHIBITION, PAVILION 1 & 2 1500 END OF SESSION 1100-1200 SESSION SIX 1500-1530 AFTERNOON TEA IN TRADE EXHIBITION, Room: River View Room 5 PAVILION 1 & 2 1100 Dr S. Eisman Fungal nails 1530-1700 LASERS AND ENERGY BASED DEVICES 1130 Dr S. Smith – BEST PRACTICE Steroid phobias Companies will develop or explain 1200 END OF SESSION treatment protocols with interested users or potential users of equipment allowing feedback and interaction. Each session 1200-1300 LUNCH IN PAVILION 1 & 2 will take 40 minutes with a 10 minute changeover period. 1300-1515 SESSION SEVEN Room: Meeting Room 6 Room: River View Room 5 1530-1610 Advanced Cosmeceuticals 1300 Dr L. Pitney 1610-1620 Changeover A case study presentation on psycho 1620-1700 Cynosure cutaneous disorders Room: Meeting Room 7 1330 M. Hoang, RN and L, McMahon, RN 1530-1610 Galderma Camouflage 1610-1620 Changeover 1400 A/Prof. P. Fernandez-Penas 1620-1700 Cryomed Metatastic skin cancer research Room: Meeting Room 8 1430 A/Prof. C. Vinciullo 1530-1610 Syneron Candela Mohs surgery in Australia: A proud history of accomplishments 1610-1620 Changeover 1500 S. Temby 1620-1700 Lumenis Australia & NZ Award presentations and member’s draw 1515 END OF SESSION

22 SCIENTIFIC PROGRAM SUNDAY 15 MAY 2016

THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

SOCIAL PROGRAM

1800-1930 GRADUATION ORATION AND Dr Christopher Heyes CONFERRING OF DIPLOMAS AND Dr David Jenkins AWARDS Dr Simon Khoury Riverside Theatre Dr Clare Koh Dr Gary Moloney Academic Procession Dr Gilberto Moreno The audience is requested to stand when Dr Vanessa Palmer the academic procession enters the hall; Dr Julia Rhodes and to remain standing for the singing Dr Niyati Sharma of the National Anthems of Australia and Dr Annika Smith New Zealand. Dr Dev Tilakaratne Opening Proceedings Dr Jenny Tu A/Prof. Chris Baker, President of the Dr Amit Verma Australasian College of Dermatologists, Dr Laura Wheller will declare the proceedings open and Australasian College of Dermatologists address the assembly Travelling Fellowship from 2015 Silver Medal Examinations Prof. Alan Cooper Dr Christopher Heyes A/Prof. Gayle Fischer Dr Julia Rhodes Certificate of Meritorious Service Founders’ Medal for Procedural Dr Patricia Lowe Dermatology for 2015 Dr Leon Wall Dr Christopher Heyes Honorary Fellow Ken Paver Medal for Medical Prof. Chee Leok Goh Dermatology For 2015 Prof. Peter Mortimer Dr Julia Rhodes Associate Member President’s Medal for Pharmacology for Dr Trevor Beer 2015 Mervyn Gold, OAM, Award Dr Jane Li Dr John Coates Adrian Johnson Memorial Prize for 2015 Graduate from the ACD Mohs Dr Emma Mooney Micrographic Surgery Training Program Eileen Collins Memorial Prize for 2015 Dr David Lim Dr Burcu Kim Dr Nicholas Stewart Oath of Ethics Fellows elected under Clause 3.2 of the The new Fellows will affirm the Oath of College Constitution Ethics. Dr Ilsphi Browne The Oath will be recited by Dr Christopher Dr Johannes Kern Heyes and Dr Julia Rhodes. Dr David Lim Dr Rose Mak John Reid Oration Dr Erin Mullan To be given by Mr John Inverarity Dr Nancy Todes-Taylor Conclusion Induction of New Fellows The assembly is requested to stand as Dr Nicola Abbott the academic procession leaves the Dr Genevieve Casey auditorium. Dr Hsien Chan Guests of the conferring ceremony are Dr Claudia Curchin invited to stay and enjoy light refreshments Dr Ryan De Cruz in the foyer outside Riverside Theatre, Perth Dr Elizabeth Ellis Convention and Exhibition Centre.

23 SCIENTIFIC PROGRAM MONDAY 16 MAY 2016

THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

0730-0845 LA ROCHE POSAY SPONSORED BREAKFAST: A FURTHER LOOK INTO THE SKIN MICROBIOME AND ITS ROLE IN CUTANEOUS DISEASE Room: BelleVue Ballroom 2 Speakers: Prof. T. Bieber and S.Seite Chair: A/Prof. P Fernandez-Penas 0845 END OF SESSION

0900-1030 INFECTIOUS 0900-1030 NONMELANOMA SKIN CANCER SYMPOSIUM DISEASE Room: Riverside Theatre SYMPOSIUM Chair: Dr T. Caccetta Room: Meeting 0900 Prof. C. Otley Rooms 1-3 Recognition and management of challenging skin cancers Chair: A/Prof. P. 0930 Prof. D. Damian Kumarasinghe Oral nicotinamide for skin cancer chemoprevention: The 4B 4A 0900 Prof. D. Elston ONTRAC study and clinical practice Infections and 0950 Dr S. Hwang infestations Meta-analysis: Interventions for preventing non-melanoma 0930 Dr T. Inglis skin cancers (NMSC) in patients with one or more previous Meliodosis and other NMSC WA infections 0958 Dr S. Smith 1000 Dr S. Allison Generation why: Sun-protective behaviours of Australian Chromoblastomycosis medical students in Australia: A 1006 Dr H. Cheng historical perspective Depth of basal cell carcinoma – does it matter? 1015 Discussion 1014 Dr L Ge CONCURRENT SESSION SESSION CONCURRENT CONCURRENT SESSION SESSION CONCURRENT 1030 END OF SESSION The first 48 months of an Australian renal and liver organ transplant dermatology database 1022 Dr J. Johnston First-in-human phase 1 safety study of BLZ-100 in subjects with skin cancer 1030 END OF SESSION

1030-1100 MORNING TEA IN TRADE EXHIBITION, PAVILION 1 & 2 SOCIAL PROGRAM 1100-1230 PLENARY 2 Room: Riverside Theatre 0700 GOLF TOURNAMENT Chair: Dr C. Baker Karrinyup Country Club 1100 Prof. C. Otley Please meet at 0645 for a Inventing in your medical career 0700 tee off 1130 Prof. P. Mortimer Managing primary lymphoedema and lymphatic 1000-1230 PRIVATE ART & HISTORY malformations WALKING TOUR OF PERTH 1200 Dr P. Leedman Meeting Point: Level 1 Melanoma research in WA Entrance, Perth Convention 1230 END OF SESSION & Exhibition Centre

1230-1345 LUNCH IN TRADE EXHIBITION, PAVILION 1 & 2 1800 MEN’S AND LADIES TENNIS TOURNAMENT 1345-1500 CLINICAL MEETING Kings Park Tennis Club Room: Riverside Theatre Delegates may depart Chair: Dr G. Masel together at 1745 from Clinico-pathological conference: An interactive session of Level 1 Entrance, Perth interesting cases Convention & Exhibition 1500 END OF SESSION Centre 1500-1530 AFTERNOON TEA IN TRADE EXHIBITION, PAVILION 1 & 2 24 SCIENTIFIC PROGRAM MONDAY 16 MAY 2016

THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

1530-1700 ANNUAL GENERAL MEETING 1530-1700 REGISTRARS’ TEACHING SESSION Room: Riverside Theatre Room: Meeting Rooms 1-3 For Fellows and Associate Members of Chair: Dr G. Parham College only 1530 Prof. J. McGrath 1700 END OF SESSION Genetic skin diseases: Can you make a diagnosis? 1555 Prof. C. Otley Tumour board for registrars 1620 Prof. D. Elston Biopsy of pigmented lesions 1640 Prof. P. Mortimer Distinguishing lymphoedema from other forms of chronic oedema 1700 END OF SESSION For vocational trainees in dermatology only

AUSTRALASIAN SOCIETY OF COSMETIC DERMATOLOGISTS 3RD ANNUAL MEETING

0730-0845 SYNERON CANDELA SPONSORED 0850-0920 SKIN TIGHTENING BREAKFAST: OVERCOMING THE Room: River View Room 4 CHALLENGE OF UNWANTED Chair: Dr M. Rich PIGMENTATION: USING THE CANDELA 0850 Dr K. Hoffman PICOWAY AND GENTLEMAX PRO Skin tightening Room: River View Room 5 0905 Dr K. Hoffman Speaker: Dr S. Eubanks Laser lipolysis Chair: 0920-1030 Speed dating with the trade Unwanted pigmentation has been a Short in depth talks delivered at trade booths challenge for many years. After trying by company representatives outlining the numerous devices, none of which could best of their equipment or products to small deliver both a safe and effective treatment groups of delegates who will be rotated that the Candela PicoWay Resolve and the through a number of stands. This will allow a GentleMAX Pro can. Both of which have non threatening educational look at the most managed to achieve these challenging recent advances in technologies requirements effectively. 1030 END OF SESSION 0845 END OF SESSION

1030-1100 MORNING TEA IN TRADE EXHIBITION, PAVILION 1 & 2 1230-1345 LUNCH IN TRADE EXHIBITION, PAVILION 1 & 2

1345-1500 MINI PLENARY 1530-1700 ASCD MEETING FOR NON Room: River View Room 4 DERMATOLOGISTS Chair: Dr M. Freeman Room: River View Room 4 1345 Dr G. Monheit Chair: A/Prof. G. Goodman Ethics and economics in cosmetic practice 1530 A/Prof. G. Goodman Physical treatments of acne How to think like a dermatologist 1405 Dr G. Monheit 1615 Dr A. Rudd Peels in the treatment of acne Skin care 1425 Dr S. Eubanks 1645 END OF SESSION Lasers and lights in the treatment of acne 1700-1830 Galderma Dummy Injecting Session 1445 Ms L. Christian Room: River View Room 4 Cosmetic camouflage for those with acne Chair: Dr L.M. Yap 1500 END OF SESSION Dr S. Cliff 1500-1530 AFTERNOON TEA IN TRADE EXHIBITION, Botulinum Toxin: Field of Effect and HA filler PAVILION 1 & 2 selection based on patient and product characteristics 1830 END OF SESSION

25 SCIENTIFIC PROGRAM TUESDAY 17 MAY 2016

THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

0730-0845 LILLY SPONSORED BREAKFAST: PATIENT CARE IN PSORIASIS: IS IT TIME TO RAISE THE THERAPEUTIC BAR? Room: BelleVue Ballroom 2 Speakers: Prof. M. Hopwood and Dr B. Nickoloff Chair: Cl. A/Prof. K. Gebauer This symposium will focus on new clinical approaches towards improving patient outcomes holistically and practical approaches for managing complex patients with expert discussions by Prof. Malcolm Hopwood and Dr Brian J Nickoloff 0845 END OF SESSION

0900-1030 ALOPECIA SYMPOSIUM 0900-1030 RESEARCH SYMPOSIUM 1 Room: Riverside Theatre Room: Meeting Rooms 1-3 Chair: Dr B. Ricciardo Chair: Dr G. Sadler 0900 Prof. D. Elston 0900 A/Prof. A. Hall Alopecia Dermatology in the Solomon Islands & Skin of 0930 Prof. R. Sinclair Colour Treatment of female pattern 0915 Dr M. Lane-Brown with low dose Laennec’s melanosis: The first modern minoxidil published description of metastatic melanoma 0940 Dr J. Li 0925 Dr C. Zhao 5B 5A Gene expression in alopecia BP230-type bullous pemphigoid (a new disease areata before, during and entity?): A case series and a review of literature after active hair loss 0935 Dr F. Shepherd TECHNOLOGY SYMPOSIUM A clinical experience in the early arthritis for psoriatic patients (EARP) screening tool: Screening 0950 A/Prof. S. Thng for psoriatic arthritis in dermatology clinic Biomedical engineering research in dermatology: 0945 Ms E. Hao The next frontier in clinical Validation of outcome measures for pemphigus: translational research A systematic review using the COSMIN criteria 1010 Dr C. Higgins 0955 Miss E. Kim Nanotechnology in Novel and recurrent keratin 5 and keratin 14 dermatology – New frontiers mutations in 38 families with epidermolysis CONCURRENT SESSION SESSION CONCURRENT CONCURRENT SESSION SESSION CONCURRENT bullosa simplex in Australia 1020 Dr S. Smith Consumer convenience 1005 Dr Q. Le or community confusion: A single-institution experience of porphyria Technology and lesion cutanea tarda (PCT) in Australia: Case series directed examination report and literature review skin cancer programs in 1015 Prof. D. Damian on behalf of Dr A. Chen pharmacies Oral nicotinamide reduces transepidermal 1030 END OF SESSION water loss: A randomised controlled trial 1025 Discussion 1030 END OF SESSION

1030-1100 MORNING TEA IN TRADE EXHIBITION, PAVILION 1 & 2

1100-1230 PLENARY 3: THE PROBLEM OF COLOUR 1145 Dr S. Eubanks Room: Riverside Theatre Erythema Chairs: Dr S. Richards and Dr B. Welsh 1200 A/Prof. G. Goodman 1100 Dr K. Hoffman Sallow skin and the concept of brightening Brown spots 1215 Dr Y. Tanaka 1115 Dr G. Monheit Intensive targeted treatment for pigmentation Brown rashes (PIH, melasma, Poikiloderma) using intense pulsed light with wavelengths 1130 Dr. K Hoffman between 500-635 nm Treatment of tattoos 1230 END OF SESSION

26 SCIENTIFIC PROGRAM TUESDAY 17 MAY 2016

THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 49TH ANNUAL SCIENTIFIC MEETING

1230-1330 LUNCH IN TRADE EXHIBITION, PAVILION 1 & 2

1330-1500 CLINICAL UPDATES 1330-1450 RESEARCH SYMPOSIUM 2 Room: Riverside Theatre Room: Meeting Rooms 1-3 Chair: Dr C. Tait Chair: Dr J. Von Nida 1330 Prof. P. Mortimer 1330 Dr V. Cox Recurrent cellulitis Case series: A review of 8 patients with drug- 1400 A/Prof. P. Foley associated systemic lupus erythematosus and Ivermectin 1% cream, an positive dsDNA after commencing anti-TNF effective and safe topical biologic agents treatment of inflammatory 1340 Dr J-M. Tan lesions of papulopustular The role of reflectance confocal microscopy rosacea in correlating the morphologic and molecular 6B 6A 1407 A/Prof. P. Foley consequences of sun exposure Comparative efficacy and 1350 Dr P. Dickison safety of ivermectin 1% cream Psoriasis patients - Knowledge of comorbidities and metronidazole 0.75% 1400 Dr S. Smith cream in the novel treatment Evaluation of the influence of pharmacists and of papulopustular rosacea: general practitioners on patient perceptions of The ATTRACT (assessment of a long-term topical use in Australia topical treatment in rosacea - 1410 Dr H. Lolatgis activity, compliance, tolerability) Drug survival of systemic treatment options in study the management of adult atopic dermatitis 1415 A/Prof. M. Rademaker 1420 Dr J. Ng CONCURRENT SESSION SESSION CONCURRENT CONCURRENT SESSION SESSION CONCURRENT Methotrexate – An expert Patient presentation patterns at the position statement dermatological clinics of three major teaching 1430 Dr J. Wells hospitals in Western Australia Establishing a multi-disciplinary 1430 Dr J. Kern service in cutaneous lymphoma Esophageal involvement in – - Experience at Westmead more prevalent than previously thought? A Hospital prospective study with suggestion of diagnostic 1445 Discussion criteria and therapeutic implications 1500 END OF SESSION 1440 Discussion 1450 END OF SESSION

1500-1515 PRESENTATION OF AWARDS AND CLOSING REMARKS Room: Riverside Theatre

27 SCIENTIFIC PROGRAM TUESDAY 17 MAY 2016

AUSTRALASIAN SOCIETY OF COSMETIC DERMATOLOGISTS 3RD ANNUAL MEETING

0900-1030 THE ISSUE OF VOLUME Room: River View Room 4 Chairs: Dr T. Poon and Dr N. Cook 0900 Dr S. Cliff Volume and it role in facial beauty 0920 Dr G. Monheit The lower face and neck – tips and tricks 0940 Dr K. Hoffman Volume and its role in projection and shape of facial features 1000 Dr G. Monheit Superficial injections for lines, wrinkles and barcodes 1015 Dr S. Cliff Volume and gender differentiation 1030 END OF SESSION

1030-1100 MORNING TEA IN TRADE EXHIBITION, PAVILION 1 & 2

1100-1230 PLENARY 3: THE PROBLEM OF COLOUR Room: Riverside Theatre Chairs: Dr S. Richards and Dr B. Welsh 1100 Dr K. Hoffman Brown spots 1115 Dr G. Monheit Brown rashes (PIH, melasma, Poikiloderma) 1130 Dr. K Hoffman Treatment of tattoos 1145 Dr S. Eubanks Erythema 1200 A/Prof. G. Goodman Sallow skin and the concept of brightening 1215 Dr Y. Tanaka Intensive targeted treatment for pigmentation using intense pulsed light with wavelengths between 500-635 nm 1230 END OF SESSION

1230-1330 LUNCH IN TRADE EXHIBITION, PAVILION 1 & 2

1330-1500 TEXTURE Room: River View Room 4 Chairs: Dr A. Rudd and A/Prof. G. Goodman 1330 Dr K. Hoffman Texture rejuvenation using picosecond technologies 1345 Dr Y. Tanaka Beneficial applications of water-filtered broad-spectrum near-infrared device 1400 A/Prof. G. Goodman Pores 1415 Dr S. Cliff The treatment of atrophic scarring 1430 Dr R. Moy Treating fine lines 1445 Discussion 1500 END OF SESSION

28 POSTER PRESENTATIONS

This year the posters will be displayed electronically in the E-Poster Lounge in the Exhibition Hall. Each television will scroll through the posters of one of the following six topics. Posters can be viewed individually on the iPad stations in the E-Poster Lounge. Delegates may also access the E-Posters on their own device via the link, http://acd2016.paperlessevents.com.au/ CANCER AND NEOPLASIA

2 N. Adler 69 S. Lee Blue naevus-like melanoma – A rare subtype of Multiple keratoacanthomas developing over skin graft melanoma: A case series and review of the literature and donor site 18 V. Chandran 70 S. Lee A curious case of inguinal keratotic lesions posing a Rosai-dorfman disease with autoimmune haemolytic diagnostic dilemma anaemia in an adult 24 V. Cox 72 M. Lin Understanding the skin cancer burden and follow up The utility of dermoscopy in the diagnosis of practices in a cohort of 199 renal transplant patients at amelanotic nodules a tertiary hospital 75 Z. Low 26 J. Davey Oral acanthosis nigricans and leser-trelat sign in A perplexing peristomal plaque: A case of peristomal metastatic serous ovarian carcinoma: Case report and intestinal metaplasia review of literature 27 K. Deen 79 R. Minocha A rare association of Sweet’s syndrome with Nicotinamide chemoprevention and multiple keratoacanthomas in a patient with underlying immunomodulation in melanoma and non-melanoma myelodysplasia skin cancer 35 P. Fernandez-Penas 82 N. Nagodavithana Label-free proteomic analysis of microdissected Chemotherapy induced vesico- bullous disseminated formalin-fixed and paraffin embedded cutaneous superficial actinic porokeratosis squamous cell carcinoma tissue 86 H. O’Rourke 38 A. Gandhi A striking facial rash leading to the diagnosis of a rare Clearance of an extramammary paget’s disease lesion haematological malignancy with milk weed latex (Euphorbia peplus): A case report 89 P. Peters 40 L. Ge Treatment of diffuse superficial actinic porokeratosis Hereditary leiomyomatosis and renal cell carcinoma using fluorouracil chemowraps syndrome : A case series 93 A. Quinn 47 A. Harris It’s not a tumour! It was, but not what we thought Neoadjuvant treatment with vismodegib of a patient 103 C. Rowe with a giant locally advanced basal cell carcinoma Intratumoural heterogeneity of Ki67 and p16 informs on survival in melanoma 48 V. Harris The operation of a tertiary referral combined chronic 108 J. Shannon lymphocytic leukaemia / dermatology clinic Hidroadenocarcinoma of the sole of foot presenting as a ‘’ 49 V. Harris Written across your forehead: A case of blastic 111 K. Sharpe plasmacytoid dendridic cell neoplasm Cutaneous leiomyoma in hereditary leiomyomatosis and renal cell cancer syndrome 53 C. Higgins Primary paget’s disease of the vulva successfully 121 P. Stevenson treated with imiquimod The efficacy of home based chemo-wraps of topical 5-fluorouracil (5-FU) for solar keratoses on the limbs: 54 S. Hwang A case series A case of cellulitis like presentation masking underlying acute lymphoedema secondary to axillary metastatic 127 A. Swarbrick melanoma Benign lymphangioendothelioma: A case report 55 S. Hwang 132 C. Thomas Case series of bullous pemphigoid associated with Attitudes towards sun, tanning and skin cancer pembrolizumab use in patients with metastatic prevention amongst Australian adults undergoing skin melanoma checks 56 S. Hwang 139 P. Tong Ipilimumab induced acute generalised exanthematous Mosaic poikiloderma heralding rothmund-thomson pustulosis (AGEP) in a patient with metastatic syndrome – Insights into genetics determinants of melanoma premature ageing and skin cancer 68 Q. Le 147 M. Zallmann A case of lymphoedema-associated disseminated blue A review of the role of magnetic resonance imaging naevi mimicking metastatic melanoma in asymptomatic infants with at-risk congenital melanocytic nevi

29 DRUG REACTIONS

3 N. Adler 85 A. O’Connor Piperacillin-tazobactam-induced linear IgA bullous Methadone-induced desquamating eruption - A new dermatosis presenting clinically as Stevens-Johnson case report a decade later syndrome/toxic epidermal necrolysis overlap 105 A. Sahebian 5 R. Anforth A review on dermatological side effects of current Norspan® (Buphenorphone) patch recall urticaria treatment regimens in lung transplant recipients 7 L. Bingham 120 P. Stevenson developing during adalimumab Lung sarcoidosis and silicosis developing in a psoriasis therapy for psoriasis: A case report patient treated with adalimumab 17 S-L. Chan 133 C. Thomas Phototoxic eruption following ingestion of chlorophyll Drug reaction with eosinophilia and systemic symptoms (DRESS) in metastatic basal cell carcinoma 22 V. Cox treated with vismodegib An unusual case of Toxic Epidermal Necrolysis with conversion to full thickness skin necrosis 138 S. Tiwari Azacitidine induced sweet’s syndrome - Two unusual 39 L. Ge clinical presentations Alopecia areata during pegylated interferon alpha-2a: A report of two cases 140 A. Thornton Acute alveolitis following infliximab therapy for 50 G. Harvey psoriasis Erythema multiforme secondary to imiquimod 146 J. Yee 59 P. Kadam The recommendations of monitoring and adverse : An extremely rare adverse effect effect profile of oral azathioprine immunosuppression of adalimumab in paediatric dermatology 74 H. Lolatgis 148 C. Zhao Persistent acne medicamentosa secondary to vitamin Debilitating late outcomes of toxic epidermal necrolysis B12 (TEN): Presentation of 2 cases

IMMUNE REACTIONS

6 E. Anthony 62 I. Kashani Linear IgA bullous dermatosis IgG4 related disease in dermatology: Case and update 10 N. Biswas 63 M. Kim Cutaneous granulomas arising in a patient with ataxia A beneficial role for colchicine in reducing granulation telangiectasia tissue in junctional epidermolysis bullosa which caused anaemia after silicone dressings were started 11 J. Bui Cutaneous pyogenic granuloma treated with 64 M. Kim intralesional triamcinolone injection: A case and A rare case of urethral involvement in erythema review multiforme (EM) major 15 M. Calao 67 L. Kunde Epidemiology of (HS) in Juvenile pityriasis rubra pilaris: An atypical Australia presentation in type 5 skin with a treatment course complicated by social issues 19 V. Chandran Necrobiotic xanthogranuloma initially presenting as 81 A. Mulcahy urticaria Subacute cutaneous lupus erythematosus presenting for an eczema trial 28 K. Deen An unusual case of lichen planus occurring in sites of 92 F. Poon cupping therapy Severe dystrophic calcinosis cutis: The need for early intervention and optimal treatment of juvenile 29 P. Dickison dermatomyositis to prevent debilitating sequaele in Axillae milia-en-plaque: An atypical presentation for adulthood primary systemic amyloidosis 94 H. Rajgopal Bala 31 P. Dickison A case series of 10 patients with steroid resistant Shooting star sarcoid alopecia areata successfully treated with 32 A. Didan azathioprine An unusual presentation of pyoderma gangrenosum 97 H. Rajgopal Bala leading to circulatory shock Two cases of generalised granuloma annulare successfully 57 T. Jeffery treated with acitretin and narrowband UVB therapy Topical crushed prednisolone use in recalcitrant 98 J. Raymond peristomal pyoderma gangrenosum Intralesional MTX injections for nodular cutaneous amyloidosis

30 POSTER PRESENTATIONS

106 J. Shannon 131 S. Tee A solitary dystrophic thumb nail that did not respond to An unusual presentation of systemic amyloidosis topical treatments was biopsied and a granulomatous presenting with localised mucocutaneous lesions reaction pattern suggestive of sarcoid was found 142 N. Valecha 130 C. Tancharoen Unilateral hidradenitis suppurativa triggered by A case of rapidly progressing angioedema with occupational exposure: A case report eosinophilia requiring treatment with high dose 144 D. Wakade corticosteroids PD-1 inhibitors induced bullous lichen planus: A rare presentation and report of three cases

INFECTIONS AND INTERNATIONAL DERMATOLOGY

9 N. Biswas 66 T. Kovitwanichkanont An atypical mycobacterial infection arising in a patient Treatment of old world cutaneous leishmaniasis – The on adalimumab treatment monash health experience 20 V. Cox 77 D. Maor A case of suspected tuberculosis seen in rural South A case of orf disease in a patient with scleroderma Australia 83 N. Nagodavithana 21 V. Cox Clinico-mycological profile of dermatophytosis - A Sri African tick-bite fever in a returned traveller Lankan experience 34 H. Edwards 107 J. Shannon Leprosy: The variety of presentation in a dermatology Case report of cryptococcus presenting as a bland outpatient clinic in India non healing ulcer on the thigh of a renal transplant patient 45 A. Gurung Escherichia coli cellulitis & myonecrosis in a patient 119 P. Stevenson with Hepatitis B A unique granulomatous skin rash leading to the diagnosis of a low grade infection in a total shoulder 60 P. Kadam replacement performed several years prior Delayed onset of the jarisch – Herxheimer reaction in lyme disease 135 S. Thomas Case discussion: Dermatophyte infection (tinea faciei) 61 P. Kadam on the face of an 11 year old boy Mycobacterium avium complex infection of the knee-joint after rituximab treatment for 137 B. Thorpe sclerodermatomyositis A 62 year old man with papular granulomatous dermatitis of uncertain aetiology mimicking leprosy

PSORIASIS AND DERMATITIS CANCER AND NEOPLASIA 8 R. Bissonnette 16 I. Chan Secukinumab maintains high levels of efficacy through A review of physical therapies for the management of 3 years of treatment: Results from an extension to a pruritus phase 3 study (SCULPTURE) 25 B. Croker 12 N. Burkhardt Collaboration?: Dermatologists, rheumatologists and A randomized, double-blind, active-and placebo psoriatic arthritis – A literature interpretation (PBO)-controlled phase 3 study of efficacy and safety 30 P. Dickison of ixekizumab (IXE), adalimumab (ADA), and placebo Scratching the surface: Characteristics of itch in therapy in patients naïve to biologic disease‑modifying psoriasis antirheumatic drugs (bDMARDs) with active psoriatic arthritis (PsA) 36 P. Foley Secukinumab demonstrates an acceptable safety 13 N. Burkhardt profile in moderate to severe plaque psoriasis: Pooled Ixekizumab for the treatment of moderate-to-severe analysis of 10 phase 2/3 studies plaque psoriasis: Sub-analysis of the Phase 3 UNCOVER trials in patients with baseline PASI>15 41 L. Ge Severe atopic dermatitis with ectodermal dysplasia: A 14 N. Burkhardt case report Near or complete resolution of psoriasis is associated with greater improvements in itch and health-related 42 A. Goh quality of life: An analysis from UNCOVER-2, a phase The effectiveness of montelukast as adjunct treatment 3 clinical trial of ixekizumab among children with atopic dermatitis: An open-label, randomized controlled trial

31 46 S. Hall 109 J. Shannon Secukinumab provides sustained improvements in the Pityriasis rubra pilaris treated with methotrexate, signs and symptoms of active psoriatic arthritis in Anti‒ acitretin and adalimumab TNF-Naïve patients and those previously exposed to 113 S. Shumack Anti-TNF Therapy: 52-week results from a randomized, Secukinumab 300 mg shows superior efficacy across double-blind, placebo-controlled phase 3 trial with subject body weight groups: Pooled analysis of phase subcutaneous dosing 3 ERASURE and FIXTURE trials 71 V. Lim 115 R. Sinclair Anxiety and depression in patients with atopic Secukinumab exhibits low immunogenicity during 104 dermatitis in a Singapore tertiary dermatological weeks of treatment in subjects with moderate to severe institute plaque psoriasis 73 A. Liyanage 116 L. Spelman Recurrent pruritic intertriginous rash with lichenoid Secukinumab demonstrates sustained efficacy in papules and purpuric patches; A case report of non- moderate to severe plaque psoriasis across disease occupational textile dye allergy severity subgroups 78 N. Martin 117 L. Spelman Efficacy and safety of dupilumab for moderate-to- Secukinumab is efficacious in the treatment of severe atopic dermatitis in adults: A pooled analysis of moderate to severe plaque psoriasis regardless of sex two phase 2 clinical trials of subjects: Pooled analysis from four phase 3 studies 88 K. Papp 118 A. Steer Two-year safety of apremilast in patients with moderate Teledermatology satisfaction in children with to severe plaque psoriasis: Results from ESTEEM 1 epidermolysis bullosa 99 J. Raymond 123 J. Sullivan Lichenoid contact dermatitis secondary to Secukinumab is effective in subjects with moderate to methylisothiazolinone severe palmoplantar psoriasis: 16 week results from 100 K. Reich the GESTURE study 52-week efficacy in patients with moderate to severe 124 J. Sullivan psoriasis continued on apremilast or switched from Secukinumab is effective in subjects with nail psoriasis: etanercept: The LIBERATE study 16 week results from the TRANSFIGURE study 101 K. Reich 149 C. Zhao Psoriasis area and severity index and weight change Validation of a novel grey-scale and atopic dermatitis during apremilast treatment of moderate to severe scores for skin of colour patients – Results from a plaque psoriasis (ESTEEM 1) multi-center study 104 D. Rubel Secukinumab delivers greater improvement in health- related quality of life compared to ustekinumab in subjects with moderate to severe plaque psoriasis: 16-week data from the CLEAR study OTHER TOPICS

1 L. Abbott 51 J. Heng Livedo vasculopathy: Treatment of diseased vessels The efficacy and safety of a 70% glycolic acid peel with with ablative methods vitamin C for the treatment of acne scars 4 S. Andrews 52 C. Higgins Tele-Derm national: The spectrum of early childhood Acute non–sexually acquired genital ulceration in a presentations post-partum woman 23 V. Cox 58 J. Johnston The positive impact of a dermatology consultative Combination topical phenytoin paste and low service in an acute paediatric and adult tertiary frequency ultrasound debridement (SONOCA-185) hospital studied over 4 months used for the treatment of a recalcitrant skin ulcers 33 A. Didan 65 M. Kim Painful leg ulceration in a hypertensive diabetic How a presentation to medical grand rounds on women- A report of a martorell ulcer with serial what makes a good dermatology consult improved photographs efficiency of consultations? 37 A. Freeman 76 S. Manoharan A new anatomical landmark for a mental nerve block Fractionated erbium: YAG laser compared to (MNB), improving the efficacy in edentulous patients traditional ablative erbium: YAG laser as delivery system for recell autologous cell harvesting device 43 K. Greive The effects of applying a moisturiser on sunscreen 80 A. Mulcahy efficacy A clinical trial unit in a dermatology private practice 44 K. Greive 84 J. Ng The physiological benefits of optimally designed Calcinosis cutis, symptom or disease? A unique case of cleansers calcinosis universalis 32 POSTER PRESENTATIONS

87 H. O’Rourke 125 A. Swarbrick Think before you ink A case series of the use of pulse itraconazole for simple 90 L. Pitney Cicatricial alopecia, nail dystrophy and bilateral 126 A. Swarbrick deafness A review of dermatology mobile apps 91 M. Polcz 128 A. Swarbrick Neurogenic rosacea: A case series Hypertriglyceridaemia, hyperglycaemia and diffuse eruptive xanthoma 95 H. Rajgopal Bala A review on oral tranexamic acid for the treatment of 129 Y. Tanaka melasma Long-term skin tightening effects of a sharply tapered non-insulated microneedle radiofrequency applicator 96 H. Rajgopal Bala with novel fractionated pulse mode shown through Granular parakeratosis: A series of five cases three-dimensional volumetric assessment 102 M. Rich 134 C. Thomas Latest developments in intravaginal procedures Self-directed tablet education session improves 110 J. Shannon safety knowledge amongst patients undergoing The intersection between psychiatry and phototherapy dermatology 136 S. Thomas 112 K. Sharpe The sequalae of metallosis resulting in skin Surgical management for the treatment of chronic pigmentation and tattooing: A full literature review eyelid lymphedema 141 N. Valecha 114 R. Sinclair Dermatology in Australian general practice: What are Familial frontal fibrosing alopecia: Treatment the most common diagnoses? with dutasteride, minoxidil and artificial hair 143 M. Vu transplantation The education of practicing pharmacists in 122 S. Strathie Page dermatology delivered via an online teaching course The mole project: Putting the paediatric dermatology 145 F. Yap service at Princess Margaret Hospital under the A review of the current sunscreen products in Australia microscope

BREAKFAST SYMPOSIUM Patient Care in Psoriasis: Is it time to raise the therapeutic bar? Eli Lilly will host a Breakfast Symposium on Saturday 17 May from 7.30 - 8.45am with expert discussions by Professor Malcolm Hopwood and Doctor Brian J Nickoloff. The Symposium will take place in The BelleVue Ballroom 2 at the Perth Conference & Exhibition Centre and will focus on new clinical approaches towards holistically improving patient outcomes and practical approaches for managing complex patients. To register, please visit Jade Riolo at the ACD ASM49 registration desk on Level 2.

Eli Lilly Australia Pty Limited 112 Wharf Rd, West Ryde, NSW 2114, Australia. ABN 39 000 233 992. AUIXE00009b Date of Preparation: April 2016

33 FLOOR PLAN OF THE TRADE EXHBITION AREA

Company Stand Number Company Stand Number A. Menarini Australia 49 Link Healthcare 20 AbbVie 53 - 56 Lumenis Australia & NZ 13 - 14 Advanced Cosmeceuticals 50 Macquarie Medical Systems 94 Allergan 95 - 96 Meda Pharmaceuticals 2-3 Aspen Pharma 82 - 83 MediBroker 33 Australasian College of Dermatologists 1 Medifit Design & Construct 69 Australian Ultra Violet Services 68 Merck Sharp & Dohme (MSD) 67 Avita Medical 59 Nice Pak Products 28 Bayer Australia 23 Novartis Pharmaceuticals 37 - 42 BrightSky Australia 80 Pfizer 35 - 36 Celgene 5 - 8 Pierre Fabre Australia 57 - 58 Cosmetiques De France 24 Pierre Fabre Dermatologie 63 Cryomed 31 - 32 Scanmedics 60 Custommed Compounding 79 Stiefel (GSK) 29 - 30 Cutera Australia 64 Stratpharma 98 Cynosure 9 - 10 Syneron Candela 51 Dermocosmetica 52 The Critical Group 19 Device Consulting 97 The Private Practice 75 Ego Pharmaceuticals 84 - 87 Venus Concept 26 Eli Lilly Australia 104 - 105 Vorotek 66 EndyMed Medical 81 The Australian Gorlin Syndrome Galderma 88 - 93 Mutual Support Group T1 HEINE Australia 16 - 17 DEBRA Australia T2 High Tech Laser Australia 4 Australia Alopecia Areata Foundation Inc T3 Ionia Medical 65 ECZEMA Association of Australasia Inc T4 Janssen-Cilag 43 - 48 Nevus Support Australia Inc T5 Johnson & Johnson Pacific 11 - 12 Vitiligo Association of Australia (VAA) T6 Key Pharmaceuticals 76 The Skin Hospital - Skin & Cancer La Roche-Posay (L’OREAL) 61 - 62 Foundation Australia T7 LEO Pharma Pty Ltd 25 & 27 Skin & Cancer Foundation Inc T8

34 ACKNOWLEDGEMENTS

The Australasian College of Dermatologists kindly acknowledges the generous support of the following sponsors in assisting with the Annual Scientific Meeting: PLATINUM SPONSOR

GOLD SPONSORS

SILVER SPONSOR

OTHER SPONSORS

Australasian College of Dermatologists PO Box 3785, RHODES NSW 2138, Australia T +61 2 8765 0242 or 1300 361 821 (within Australia only) F +61 2 9736 2194 E [email protected] W http://www.dermcoll.edu.au

ASM 2016 Secretariat PO Box 576, CROWS NEST NSW 1585, Australia T +61 2 9431 8600 F +61 2 9431 8677 E [email protected]

35 CLEAR SKIN*1-3 PBS LISTED 1st September, 20154

*PASI 100 was achieved in 41.6 and 36.8 of patients with Cosentyx 300 mg at week 16.1,3

PBS Information: Authority required for the treatment of severe chronic plaque psoriasis. Refer to PBS Schedule for full Authority information.

See Approved Product Information before prescribing. Approved Product Information available on request. or the most up-to-date Product Information, go to http://www.novartis.com.au/products_healthcare.html. COSENTYX® (secukinumab). Indication: the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Dosage and administration: The recommended dose is 300 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg. Contraindications: Severe hypersensitivity reactions to the active substance or to any of the excipients. Precautions: Infections: Caution in patients with chronic or history of recurrent infection. If a patient develops a serious infection, the patient should be closely monitored and Cosentyx should not be administered until the infection resolves. Anti-tuberculosis therapy should be considered prior to initiation of Cosentyx in patients with latent tuberculosis. Cosentyx should not be given to patients with active tuberculosis. Crohns disease: Patients with active Crohns disease treated with Cosentyx should be followed closely. ypersensitivity reactions: Administration of Cosentyx should be discontinued immediately and appropriate therapy initiated if an anaphylactic or other serious allergic reaction occurs. Latex-sensitive individuals: The removable cap of the Cosentyx pre-fi lled syringes/pen contains a derivative of natural rubber latex. Vaccinations: Cosentyx should not be given concurrently with live vaccines. Pregnancy: Cosentyx should be used during pregnancy only if the benefi ts clearly outweigh the potential risks. Breast-feeding: Caution should be exercised when Cosentyx is administered to a woman who is breast-feeding. Interactions: Live vaccines should not be given concurrently with Cosentyx. Side effects: Very common ( 10): nasopharyngitis. Common (1 to 10): upper respiratory tract infection, rhinitis, pharyngitis, oral herpes, diarrhoea, urticaria, rhinorrhoea. Uncommon (0.1 to 1): sinusitis, tonsillitis, oral candidiasis, neutropenia, tinea pedis, conjunctivitis (cos080115m). References: 1. Cosentyx TA Approved Product Information. Novartis Pharmaceuticals Australia Pty Limited. January 2015. 2. Thaci D et al. J Am Acad Dermatol 2015;73:400–9. 3. Langley R et al. N Engl J Med 2014;371:326–38. 4. Pharmaceutical Benefi ts Scheme. Available at: www.pbs.gov.au. Accessed November 2015. Novartis Pharmaceuticals Australia Pty Ltd, ABN 18 004 244 160, 54 Waterloo Road, North Ryde NSW 2113. Registered trademark of Novartis Pharmaceuticals. Date of preparation: January 2016. SKM 0379 CS0049